TENX

Tenax Therapeutics, Inc. NASDAQ Listed Apr 4, 1994

Healthcare ·Biotechnology ·US · tenaxthera.com

$11.58

Mkt Cap $199.1M

52w Low $5.34 47.9% of range 52w High $18.38

50d MA $13.79 200d MA $10.22

P/E (TTM) -9.5x

EV/EBITDA -6.7x

P/B 5.2x

Debt/Equity 0.0x

ROE -54.2%

P/FCF -13.4x

RSI (14) —

ATR (14) —

Beta 1.19

50d MA $13.79

200d MA $10.22

Avg Volume 368.1K

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

SIC Code

2834

CIK (SEC)

34956

Phone

919 855 2100

ONE Copley Parkway · Chapel Hill, NC 27560 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-1.26	-0.38	+69.8%	14.51	+1.6%	+0.8%	-2.9%	-2.5%	+1.0%	+8.5%	—
Nov 12, 2025	AMC	-1.33	-0.40	+69.9%	6.99	-1.7%	-4.3%	+6.1%	+3.5%	+4.6%	-4.8%	—
Aug 13, 2025	AMC	-0.50	-0.27	+46.0%	5.91	-1.5%	+0.7%	+0.3%	+0.7%	+0.2%	-0.7%	—
May 14, 2025	AMC	-0.48	-0.28	+41.7%	5.68	+1.2%	+0.4%	+3.3%	+2.2%	-0.3%	+1.2%	—
Mar 25, 2025	AMC	-0.52	-0.18	+65.4%	6.26	+7.2%	-2.1%	+0.8%	+5.0%	+0.9%	-2.9%	—
Nov 13, 2024	AMC	-1.38	-0.19	+86.2%	4.75	+2.1%	+4.0%	-1.4%	-0.8%	+0.6%	-1.9%	—
Aug 13, 2024	AMC	-1.99	-1.83	+8.0%	4.03	-0.7%	-2.0%	+1.3%	+4.8%	+1.4%	-2.6%	—
May 14, 2024	AMC	-2.40	-3.12	-30.0%	3.47	+4.0%	+3.5%	-1.1%	+0.0%	+6.2%	-2.7%	—
Mar 28, 2024	AMC	-8.14	-12.98	-59.5%	4.24	-2.1%	-9.9%	+1.3%	+6.2%	-7.1%	+0.0%	—
Nov 13, 2023	AMC	-7.20	-6.40	+11.1%	49.60	-17.7%	-18.5%	-1.2%	-15.8%	-9.3%	-5.2%	—
Aug 14, 2023	AMC	-0.10	-4.00	-3900.0%	23.36	+9.6%	+2.7%	+8.0%	+1.9%	+10.6%	+13.2%	—
May 15, 2023	AMC	-0.37	-12.00	-3143.2%	26.56	+0.9%	-13.6%	+1.4%	+4.1%	+2.3%	+5.8%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 16	Guggenheim	Maintains	Buy → Buy	—	$13.84	$14.42	+4.2%	+1.0%	+8.5%	+2.6%	-4.2%	-4.1%
Dec 17	Guggenheim	Maintains	Buy → Buy	—	$11.16	$11.30	+1.3%	+5.6%	+8.7%	+2.2%	-4.9%	-4.0%
Aug 14	Guggenheim	Maintains	Buy → Buy	—	$5.91	$5.82	-1.5%	+0.7%	+0.3%	+0.7%	+0.2%	-0.7%
Feb 20	Roth MKM	Maintains	Buy → Buy	—	$4.15	$4.23	+1.9%	-3.9%	+9.0%	-6.2%	-2.5%	-0.8%
Nov 13	Roth MKM	Maintains	Buy → Buy	—	$12.48	$25.04	+100.6%	+297.4%	-18.5%	-1.2%	-15.8%	-9.3%
May 18	Ladenburg Thalmann	Upgrade	Neutral → Buy	—	$15712.00	$15936.00	+1.4%	-1.2%	+3.7%	+2.4%	-0.2%	+1.2%

Data updated apr 27, 2026 4:27am · Source: massive.com